AcelRx Pharmaceuticals Joins Russell Global and Russell 3000 Indexes
REDWOOD CITY, Calif., July 2, 2013
REDWOOD CITY, Calif., July 2, 2013 /PRNewswire/ --AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, has joined the broad-market Russell 3000^® Index
and the Russell Global^® Index according to the final membership lists posted
July 1, 2013.
Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest
U.S. stocks as of the end of May, ranking them by total market capitalization.
Membership in the Russell 3000, which remains in place for one year, means
automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style indexes. The
Russell 3000 also serves as the U.S. component to the Russell Global Index.
Russell indexes are used by investment managers and institutional investors
for index funds and as benchmarks for both passive and active investment
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. Zalviso^TM, AcelRx's lead product
candidate, is designed to solve the problems associated with post-operative
intravenous patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine, the
invasive IV route of delivery and the complexity of infusion pumps. Zalviso
has successfully completed all three of its planned Phase 3 clinical trials
and a New Drug Application submission is planned for the third quarter of
2013. AcelRx has announced positive top-line results for a Phase 2 trial for
ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute
pain, funded through a grant from U.S. Army Medical Research and Materiel
Command. The company has two additional pain treatment product candidates,
ARX-02 and ARX-03, which have completed Phase 2 clinical development.For
additional information about AcelRx's clinical programs please visit
Forward Looking Statements
This press release contains forward-looking statements, including, but not
limited to, statements related to the therapeutic potential of Zalviso and
other AcelRx pharmaceutical product candidates, the timing of the Company's
planned New Drug Application submission, and the planned or anticipated future
clinical development of AcelRx Pharmaceuticals' product candidates. These
forward-looking statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and uncertainties.
AcelRx Pharmaceuticals' actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without limitation,
risks related to: the success, cost and timing of AcelRx Pharmaceuticals'
product development activities and clinical trials; the uncertain and
time-consuming regulatory process; the market potential for its product
candidates; and other risks detailed in the "Risk Factors" and elsewhere in
AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings,
including its Quarterly Report on Form 10-Q filed with the SEC on May 8,
2013. AcelRx Pharmaceuticals undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of new
information, future events or changes in its expectations.
SOURCE AcelRx Pharmaceuticals, Inc.
Contact: Jim Welch, Chief Financial Officer, AcelRx Pharmaceuticals, Inc.,
Press spacebar to pause and continue. Press esc to stop.